US Supreme Court lets stand ruling that invalidated Bayer Schering's Yasmin patent
This article was originally published in Scrip
The US Supreme Court has declined to hear an appeal from Bayer Schering Pharma, ending the innovator's effort to overturn rulings invalidating a key US patent for the oral contraceptive Yasmin (drospirenone plus ethinylestradiol). The innovator had asked the high court to reconsider a decision favouring Teva Pharmaceutical Industries' Barr unit. Barr had challenged the Bayer patent.